| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marise Machielsen, Albertine Scheltema Beduin, Nienke Dekker, René S Kahn, Don H Linszen, Jim van Os, Durk Wiersma, Richard Bruggeman, Wiepke Cahn, Lieuwe de Haan, Lydia Krabbendam, Inez Myin-Germey. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. Journal of psychopharmacology (Oxford, England). vol 26. issue 1. 2012-08-21. PMID:21768161. |
differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. |
2012-08-21 |
2023-08-12 |
human |
| Marisa Möller, Jan L Du Preez, Robin Emsley, Brian H Harve. Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by sub-chronic clozapine treatment. Neuropharmacology. vol 62. issue 8. 2012-08-10. PMID:22426240. |
these changes are reversed by clozapine, emphasising the importance of these findings for the neurobiology and treatment of schizophrenia. |
2012-08-10 |
2023-08-12 |
rat |
| Maria Elena Bringas, Julio César Morales-Medina, Yaredi Flores-Vivaldo, Jose Vicente Negrete-Diaz, Patricia Aguilar-Alonso, Bertha Alicia León-Chávez, Zayda Lazcano-Ortiz, Elibeth Monroy, Antonio Rodríguez-Moreno, Rémi Quirion, Gonzalo Flore. Clozapine administration reverses behavioral, neuronal, and nitric oxide disturbances in the neonatal ventral hippocampus rat. Neuropharmacology. vol 62. issue 4. 2012-07-27. PMID:22207157. |
clozapine is widely used in the treatment of schizophrenia; however its complete mechanism of action is not fully established. |
2012-07-27 |
2023-08-12 |
rat |
| Renan P Souza, Arun K Tiwari, Nabilah I Chowdhury, Rolando B Ceddia, Jeffrey A Lieberman, Herbert Y Meltzer, James L Kennedy, Daniel J Mülle. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. Journal of psychiatric research. vol 46. issue 4. 2012-07-20. PMID:22305490. |
to accomplish this, ten polymorphisms in 208 schizophrenia or schizoaffective disorder patients treated with clozapine, haloperidol, risperidone or olanzapine for up to 14 weeks were analyzed. |
2012-07-20 |
2023-08-12 |
Not clear |
| Rune Andreas Kroken, Erik Johnse. Is rational antipsychotic polytherapy feasible? A selective review. Current psychiatry reports. vol 14. issue 3. 2012-07-19. PMID:22415638. |
no solid evidence supporting antipsychotic combinations with clozapine for treatment-resistant patients with schizophrenia was identified. |
2012-07-19 |
2023-08-12 |
Not clear |
| Rune Andreas Kroken, Erik Johnse. Is rational antipsychotic polytherapy feasible? A selective review. Current psychiatry reports. vol 14. issue 3. 2012-07-19. PMID:22415638. |
the reason for this may be that most combinations with clozapine increase the d(2)-receptor blockade, and this strategy is probably not efficient for patients with treatment-resistant schizophrenia. |
2012-07-19 |
2023-08-12 |
Not clear |
| Sònia Darbra, Laura Mòdol, Marc Pallarè. Allopregnanolone infused into the dorsal (CA1) hippocampus increases prepulse inhibition of startle response in Wistar rats. Psychoneuroendocrinology. vol 37. issue 4. 2012-07-16. PMID:21871738. |
a possible role of neurosteroids in schizophrenia has recently been suggested, as clozapine and olanzapine treatments increase brain and plasma levels of the neurosteroid allopregnanolone (allop). |
2012-07-16 |
2023-08-12 |
rat |
| Takefumi Suzuki, Gary Remington, Hiroyuki Uchida, Tarek K Rajji, Ariel Graff-Guerrero, David C Mam. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs & aging. vol 28. issue 12. 2012-07-03. PMID:22117095. |
the gold standard for treatment-resistant schizophrenia is clozapine. |
2012-07-03 |
2023-08-12 |
Not clear |
| Takefumi Suzuki, Gary Remington, Hiroyuki Uchida, Tarek K Rajji, Ariel Graff-Guerrero, David C Mam. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs & aging. vol 28. issue 12. 2012-07-03. PMID:22117095. |
however, almost all of the studies of clozapine to date have effectively excluded older patients with schizophrenia. |
2012-07-03 |
2023-08-12 |
Not clear |
| T A P Lett, T J M Wallace, N I Chowdhury, A K Tiwari, J L Kennedy, D J Mülle. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Molecular psychiatry. vol 17. issue 3. 2012-06-29. PMID:21894153. |
second-generation antipsychotics (sgas), such as risperidone, clozapine and olanzapine, are the most common drug treatments for schizophrenia. |
2012-06-29 |
2023-08-12 |
Not clear |
| Michael Kluge, Hubertus Himmerich, Peter M Wehmeier, Christine Rummel-Kluge, Mira Dalal, Dunja Hinze-Selch, Thomas Kraus, Ralf W Dittmann, Thomas Pollmächer, Andreas Schul. Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine. Schizophrenia research. vol 135. issue 1-3. 2012-06-26. PMID:22257975. |
sleep propensity at daytime as assessed by multiple sleep latency tests (mslt) in patients with schizophrenia increases with clozapine and olanzapine. |
2012-06-26 |
2023-08-12 |
human |
| Desiree D Dickerson, Aleisha M Restieaux, David K Bilke. Clozapine administration ameliorates disrupted long-range synchrony in a neurodevelopmental animal model of schizophrenia. Schizophrenia research. vol 135. issue 1-3. 2012-06-26. PMID:22260963. |
clozapine administration ameliorates disrupted long-range synchrony in a neurodevelopmental animal model of schizophrenia. |
2012-06-26 |
2023-08-12 |
rat |
| Desiree D Dickerson, Aleisha M Restieaux, David K Bilke. Clozapine administration ameliorates disrupted long-range synchrony in a neurodevelopmental animal model of schizophrenia. Schizophrenia research. vol 135. issue 1-3. 2012-06-26. PMID:22260963. |
we investigated whether acute clozapine treatment might function therapeutically by ameliorating the deficit in theta frequency coherence between the prefrontal cortex and the hippocampus that is induced in rats exposed to maternal immune activation (mia)--a risk-factor for schizophrenia. |
2012-06-26 |
2023-08-12 |
rat |
| Amir Krivoy, Liron Malka, Tsvi Fischel, Abraham Weizman, Avi Valevsk. Predictors of clozapine discontinuation in patients with schizophrenia. International clinical psychopharmacology. vol 26. issue 6. 2012-06-25. PMID:21849905. |
predictors of clozapine discontinuation in patients with schizophrenia. |
2012-06-25 |
2023-08-12 |
Not clear |
| Amir Krivoy, Liron Malka, Tsvi Fischel, Abraham Weizman, Avi Valevsk. Predictors of clozapine discontinuation in patients with schizophrenia. International clinical psychopharmacology. vol 26. issue 6. 2012-06-25. PMID:21849905. |
clozapine has superior efficacy for treating patients with schizophrenia. |
2012-06-25 |
2023-08-12 |
Not clear |
| Amir Krivoy, Liron Malka, Tsvi Fischel, Abraham Weizman, Avi Valevsk. Predictors of clozapine discontinuation in patients with schizophrenia. International clinical psychopharmacology. vol 26. issue 6. 2012-06-25. PMID:21849905. |
we attempted to identify the clinical parameters that could predict clozapine discontinuation in patients diagnosed as having schizophrenia by conducting a retrospective analysis of all of those who started on clozapine treatment during their hospitalization in our institution between 2002 and 2008 (n=100). |
2012-06-25 |
2023-08-12 |
Not clear |
| Amir Krivoy, Liron Malka, Tsvi Fischel, Abraham Weizman, Avi Valevsk. Predictors of clozapine discontinuation in patients with schizophrenia. International clinical psychopharmacology. vol 26. issue 6. 2012-06-25. PMID:21849905. |
these findings indicate that patients with schizophrenia with those risk factors need special incentives to be compliant during the first year of clozapine treatment to minimize the negative sequelae of clozapine discontinuation. |
2012-06-25 |
2023-08-12 |
Not clear |
| Umberto Mico', Antonio Bruno, Gianluca Pandolfo, Vincenzo Maria Romeo, Domenico Mallamace, Concetta D'Arrigo, Edoardo Spina, Rocco A Zoccali, Maria Rosaria A Muscatell. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. International clinical psychopharmacology. vol 26. issue 6. 2012-06-25. PMID:21934625. |
duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. |
2012-06-25 |
2023-08-12 |
Not clear |
| Umberto Mico', Antonio Bruno, Gianluca Pandolfo, Vincenzo Maria Romeo, Domenico Mallamace, Concetta D'Arrigo, Edoardo Spina, Rocco A Zoccali, Maria Rosaria A Muscatell. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. International clinical psychopharmacology. vol 26. issue 6. 2012-06-25. PMID:21934625. |
the present 16-week double-blind, randomized, placebo-controlled trial study aimed to explore the efficacy and tolerability of duloxetine add-on pharmacotherapy on clinical symptomatology and executive cognitive functioning in a sample of patients with treatment-resistant schizophrenia receiving clozapine. |
2012-06-25 |
2023-08-12 |
Not clear |
| Jimmi Nielsen, Charlotte Emborg, Susanne Gydesen, Jesper Dybbro, Jørgen Aagaard, Karsten Haderup, Pia Glyngdal, Susanne Fabricius, Dorrit Thode, Henrik Lublin, Torben Andersen, Per Damkier, David Taylo. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. Journal of clinical psychopharmacology. vol 32. issue 2. 2012-06-18. PMID:22367659. |
the study design was a 12-week, double-blind, randomized, placebo-controlled study including patients with international statistical classification of diseases, 10th revision schizophrenia (f20.0-f20.3) and treated with clozapine for at least 6 months who had not achieved sufficient response. |
2012-06-18 |
2023-08-12 |
Not clear |